Supernus Pharmaceuticals, Inc. (SUPN : NASDAQ)
Common Stock
$28.15
USD
-13.77 (-32.85%)
Last updated: 2026-11-03
Dividend Declared
Yesterday$8.1300 USD per share dividend. Ex-dividend date: November 3, 2026 • Payment date: November 6, 2026Upcoming
Follow SUPN
SUPN
Supernus Pharmaceuticals, Inc.
WealthAwesomePerformance
1 Day
-32.85%
1 Week
-31.27%
1 Month
-33.58%
YTD
-35.41%
Key Statistics
Market Cap
$1.64B
52W High
$33.22
52W Low
$21.48
P/E Ratio
-
50 Day MA
$35.18
200 Day MA
$35.68
Beta
0.52
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/3/2026 | $28.35 | $31.62 | $27.97 | $28.15 | $28.15 | 7,824,982 |
| 11/2/2026 | $41.92 | $41.92 | $41.92 | $41.92 | $41.92 | 0 |
| 10/30/2026 | $42.07 | $43.72 | $39.53 | $41.92 | $41.92 | 2,818,900 |
| 10/29/2026 | $44.24 | $44.31 | $40.75 | $41.84 | $41.84 | 1,885,190 |
| 10/28/2026 | $40.46 | $41.18 | $39.67 | $41.08 | $41.08 | 1,033,662 |
| 10/27/2026 | $40.57 | $41.20 | $39.87 | $40.96 | $40.96 | 1,075,467 |
| 10/26/2026 | $40.72 | $40.87 | $39.58 | $40.77 | $40.77 | 881,002 |
| 10/23/2026 | $41.68 | $41.95 | $39.96 | $40.70 | $40.70 | 1,159,300 |
| 10/22/2026 | $41.52 | $42.09 | $40.73 | $42.07 | $42.07 | 855,314 |
| 10/21/2026 | $41.23 | $42.00 | $40.86 | $41.21 | $41.21 | 1,005,963 |
Analyst Price Targets
Based on 4 analysts covering SUPN · as of Oct 16, 2026
Wall Street analysts forecast SUPN stock price to rise 114.9% over the next 12 months.
Consensus
Strong Buy4.50 / 5.00
Avg. Target
US$60.50
+114.9% Upside
Previously US$61.75 on Oct 5, 2026
Current Price
US$28.15
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SUPN's historical volatility
30-Day Vol
120.2%
Annualized
90-Day Vol
75.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$23.55
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$26.52 | US$17.52 – US$40.16 |
| 60 trading days | US$24.99 | US$13.90 – US$44.93 |
| 90 trading days | US$23.55 | US$11.48 – US$48.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Financials
- Revenue (TTM)
- $865.11M
- EBITDA
- $116.03M
- Profit Margin
- -5.07%
- ROE (TTM)
- -4.15%
- EPS (Diluted)
- -0.76
- Book Value
- 18.24
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Recent Dividends
$8.1300USD
Ex: Nov 3, 2026
Pay: Nov 6
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About SUPN.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| CHSN | Chanson International Holding Class A Ordinary Shares | $3.38 | +241.24% |
| RDAC | Rising Dragon Acquisition Corp. Ordinary Shares | $11.30 | +121.57% |
| MERC | Mercer International Inc | $0.21 | +68.25% |
| PARA | Parabolic Technologies, Inc. | $2.72 | +60.95% |
| KTTA | Pasithea Therapeutics Corp | $0.53 | +44.02% |
| FEED | ENvue Medical Inc. | $0.35 | +40.00% |
| IFBD | Infobird Co Ltd | $1.43 | +38.83% |
| CRMT | Americas Car-Mart Inc | $1.21 | +32.73% |
SUPN.US news timeline
1 article covering SUPN.US, most recent first
Latest